Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
How would you approach treatment for local chest wall recurrence while on Anastrozole for a postmenopausal woman with ER+ IDC s/p mastectomy?
What systemic therapy would you use?
Related Questions
Given possible lack of benefit findings in subset analysis of Monarch 3, would you still use Abemaciclib in a postmenopausal woman with high-risk ER+ breast cancer?
How do you interpret the EBCTCG meta-analysis analyzing the magnitude of benefit of anthracyclines in early stage ER+ breast cancer?
How do you treat inflammatory breast cancer (HR+, HER2 1+) treated with NAC (ACT) and mastectomy, with multifocal subcentimeter residual disease that on retesting is HR+, HER 2 2+ FISH amplified?
How would you manage a HR+/HER2+ breast cancer patient with no response during neoadjuvant TCHP?
What are your top takeaways from SABCS 2023?
Do you approach systemic therapy any differently for patients with locally advanced relapses of TNBC with metaplastic squamous differentiation, as opposed to patients with TNBC?
What would be your treatment approach in a premenopausal BRCA2+ patient with cT2N0 grade 2-3, ER negative, PR variably positive (30%; staining weak to high), HER2 negative breast cancer?
How would you discuss the prognosis of HR-positive early breast cancer in an elderly >90 patient who elects against surgery in favor of endocrine treatment only?
For which patients, if any, do you typically order additional imaging workup for staging in early-stage breast cancer?
How would you treat rapidly growing inflammatory breast cancer, invasive lobular triple negative subtype, after two cycles of neoadjuvant keynote 522?
